IMMUNEONCIA THERAPEUTICS
ImmuneOncia is an immuno-oncology-centric biopharmaceutical company. Established in 2016 as a joint venture company between Yuhan (51%) and Sorrento (49%), ImmuneOncia will leverage both companiesโ expertise in drug development and antibody engineering. Our mission is to bring safe, effective, and novel immunotherapies to oncology patients world-wide. ImmuneOnciaโs portfolio includes diverse immune checkpoint antibodies; the lead antibody IMC-001 is in Phase 1 clinical trial. Yuhan Corporati... on is a South Korea-based healthcare company founded in 1926. The company has positioned itself as one of the top pharmaceutical companies in terms of market cap and sales revenue in Korea. The core business consists of primary & specialty care, dietary supplements, household & animal care, and contract manufacturing of active pharmaceutical ingredients. It has a number of subsidiaries and a global presence in the form of joint ventures with Janssen (Belgium), the Clorox Company (USA), and Kimberly-Clark Corporation (USA). Yuhan (000100:KS) is a publicly-listed company traded on the Korea Stock Exchange.
IMMUNEONCIA THERAPEUTICS
Industry:
Biotechnology Medical Pharmaceutical
Founded:
2016-09-01
Address:
Seongnam, Kyonggi-do, South Korea
Country:
South Korea
Website Url:
http://www.immuneoncia.com
Total Employee:
11+
Status:
Active
Contact:
+82 (31) 306-8186
Email Addresses:
[email protected]
Total Funding:
40 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Google Font API Apple Mobile Web Clips Icon WordPress Font Awesome Wordpress Plugins Sitelinks Search Box Microsoft Exchange Online
Similar Organizations
Accent Therapeutics
Accent Therapeutics is a biopharmaceutical company.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Hangzhou Just Biotherapeutics (Just China)
Hangzhou Just Biotherapeutics is a comprehensive high-tech design company.
Hope Medicine
Hope Medicine is a science-driven clinical stage biopharmaceutical company
Leap Therapeutics
Leap Therapeutics is a clinical-stage biopharmaceutical company.
Werewolf Therapeutics
Werewolf Therapeutics operates as an oncology biotherapeutics company.
Current Employees Featured
Investors List
Paratus Investment
Paratus Investment investment in Private Equity Round - Immuneoncia Therapeutics
Official Site Inspections
http://www.immuneoncia.com Semrush global rank: 3.25 M Semrush visits lastest month: 5.1 K
- Host name: 112.175.14.4
- IP address: 112.175.14.4
- Location: Seoul South Korea
- Latitude: 37.5985
- Longitude: 126.9783
- Timezone: Asia/Seoul
- Postal: 02878
More informations about "Immuneoncia Therapeutics"
About us - ์ด๋ฎจ์จ์์
About ImmuneOncia Therapeutics, Inc. ImmuneOncia is an immuno-oncology-centric biopharmaceutical company. Established in 2016 as a joint venture company between Yuhan โฆSee details»
Immuneoncia Therapeutics - Crunchbase Company Profile
ImmuneOncia is an immuno-oncology-centric biopharmaceutical company. Established in 2016 as a joint venture company between Yuhan (51%) and Sorrento (49%), ImmuneOncia will โฆSee details»
HOME - ์ด๋ฎจ์จ์์
Immunotherapy, Cancer, ๋ฉด์ญํญ์์น๋ฃ, Immuno-oncology, PD-L1See details»
ImmuneOncia Therapeutics Inc. - LinkedIn
ImmuneOncia is an immuno-oncology-centric biopharmaceutical company. Established in 2016 as a joint venture company between Yuhan and Sorrento, ImmuneOncia will leverage both โฆSee details»
ImmuneOncia Therapeutics Company Profile | Management and
ImmuneOncia Therapeutics Profile and History. ImmuneOncia is an immuno-oncology-centric biopharmaceutical company. Established in 2016 as a joint venture company between Yuhan โฆSee details»
ImmuneOncia Company Profile 2024: Valuation, Funding
When was ImmuneOncia founded? ImmuneOncia was founded in 2016. Where is ImmuneOncia headquartered? ImmuneOncia is headquartered in Yongin, South Korea. What is the size of โฆSee details»
ImmuneOncia Therapeutics - Overview, News & Similar
Who is ImmuneOncia Therapeutics. ImmuneOncia is an immuno-oncology-centric biopharmaceutical company. Established in 2016 as a joint venture company between Yuhan โฆSee details»
ImmuneOncia Therapeutics Inc. - Company Profile & Staff
ImmuneOncia is an immuno-oncology-centric biopharmaceutical company. Established in 2016 as a joint venture company between Yuhan and Sorrento, ImmuneOncia will leverage both โฆSee details»
ImmuneOncia - Company Profile - Tracxn
Nov 30, 2024 ImmuneOncia - Developer of monoclonal and specific antibody for cancer treatment. Raised a total funding of $60.5M over 2 rounds from 9 investors. ImmuneOncia has โฆSee details»
Immuneoncia Therapeutics Company Profile - Office Locations
Immuneoncia Therapeutics has 5 employees at their 1 location and $40 m in total funding,. See insights on Immuneoncia Therapeutics including office locations, competitors, revenue, โฆSee details»
3D Medicines and ImmuneOncia Signed Exclusive License โฆ
Shanghai, March 31, 2021 - 3D Medicines Inc.(3DMed), a biopharmaceutical company focused on treating cancer as a chronic disease, and ImmuneOncia Therapeutics, Inc., a clinical-stage โฆSee details»
Immuneoncia Therapeutics - Funding, Financials, Valuation
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors ... Jan 17, 2022: Venture Round - Immuneoncia Therapeutics . 8: โฆSee details»
Novel immunotherapies to combine with PD-1/PD-L1 treatment
With an international approach to open innovation, ImmuneOncia Therapeutics was established in 2016 as a joint venture between Sorrento Therapeutics, Inc., a clinical-stage โฆSee details»
ImmuneOncia Therapeutics, Inc DMF, CEP, Written Confirmations, โฆ
ImmuneOncia is an immuno-oncology-centric biopharmaceutical company. Established in 2016 as a joint venture company between Yuhan (51%) and Sorrento (49%), ImmuneOncia will โฆSee details»
Novel immunotherapies to combine with PD-1/PD-L1 treatment
Pany. At the same time, ImmuneOncia will continue to make the most of its international joint venture in immuno-oncology by forging multinational and regional alliances, and networking โฆSee details»
ImmuneOncia - Raised $60.5M Funding from 9 investors - Tracxn
Nov 20, 2024 ImmuneOncia has raised a total funding of $60.5M over 2 rounds from 9 investors. Investors include LB Investment, Premier Partners and 7 others. Their latest funding round โฆSee details»
ImmuneOncia to develop immunotherapy drug - Korea JoongAng โฆ
Aug 19, 2019 Under the deal, ImmuneOncia will be provided with a yearโs worth of research funds to push for the Phase 1 clinical trial. The amount of funding was not revealed. The โฆSee details»
immunotherapy - ์ด๋ฎจ์จ์์
Immunotherapy, Cancer, ๋ฉด์ญํญ์์น๋ฃ, Immuno-oncology, PD-L1See details»
ImmuneOncia has been selected by the Korea Drug Development โฆ
Sep 19, 2019 ImmuneOncia has been selected by the Korea Drug Development Fund to develop an immune therapy targeting a cancer-aiding protein.See details»
Pipeline - ์ด๋ฎจ์จ์์
ImmuneOncia is also currently developing additional antibodies targeting novel immune-checkpoints. References. Immunity. 2013;39:1-10 : Oncology Meets Immunology: The Cancer โฆSee details»